Cost-effectiveness of pegfilgrastim versus six days of filgrastim for preventing febrile neutropenia in breast cancer patients

Tumori

Volumn 95, Issue 2, 2009, Pages 219-226

  Danova, Marco ^a   Chiroli, Silvia ^b   Rosti, Giovanni ^c,e   Doan, Quan V ^d  

^a IRCCS Policlinico San Matteo Foundation   (Italy)

^b Amgen Italia SpA   (Italy)

^c Regional Hospital   (Italy)

^d CERNER CORPORATION   (United States)

^e OSPEDALE CA FONCELLO   (Italy)

Author keywords

Key words: cost effectiveness, febrile neutropenia, filgrastim, pegfilgrastim.

Indexed keywords

ANTINEOPLASTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG COST; DRUG FATALITY; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMAN; ITALY; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 67649126886     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160909500214     Document Type: Article

References (42)

1. Skipper HE, Schabel FM, Lloyd HH: Dose-response and tumour cell repopulation rate in chemotherapeutic trials. Adv Cancer Chemother, 1: 205-253, 1979.
2. Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. ] Clin Oncol, 2: 1281-1288, 1984.
3. Norton L: A Gompertzian model of human breast cancer growth. Cancer Res, 48: 7067-7071, 1988.
4. Gardner SN: A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and non-specific drugs. Cancer Res, 60: 1417-1425, 2000.
5. Skipper HE: Kinetics of mammary tumour cell growth and implications for therapy. Cancer, 28: 1479-1499, 1971.
6. Lyman GH: Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence. ] Natl Compr Cane Netw, 3: 557-571, 2005.
7. Aapro MS, Cameron DA, Pettengell R, Bohlius 1, Crawford J, Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C; European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party: EORTC guidelines for the use of granulocyte colony stimulating factor to reduce the incidence of chemotherapy induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer, 42: 2433-2453, 2006.
8. Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatze-meier U, Lebeau B, Depierre A, Johnson P, Decoster G, Tomita D: Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer, 29A: 319-324, 1993.
9. Vogei CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Bara-jas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS: First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multi-center, double blind placebo controlled phase III study. J Clin Oncol, 23: 1178-1184, 2005.
10. Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G: Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin, 23: 2283-2295, 2007.
11. Kuderer NM, Dale DC, Crawford J, Lyman GH: Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol, 25: 3158-3167, 2007.
12. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Woz-niak AJ, Wolff AC: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol, 24:3187-3205,2006.
13. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT: Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer, 103:1916-1924, 2005.
14. Kuderer NM, Dale DC, Crawford J, Cosier LE, Lyman GH: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer, 106: 2258-2266, 2006.
15. Timmer-Bonte JN, Adang EM, Smit HJ, Biesma B, Wilschut FA, Bootsma GR de Boo TM, Tjan-Heijnen VC: Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in patients with small-cell lung cancer. J Clin Oncol, 24: 2991-2997, 2006.
16. Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG: Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacotherapy, 40: 402-407, 2006.
17. Von Minckwitz G, Kiimmel S, du Bois A, Eiermann W, Eidt-mann H, Gerber B, Hilfrich J, Huober J, Costa S, Jackisch C, Grasshoff S, Vescia S, Skacel T, Loibl S, Mehta KM, Kauf-mann M: Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophos-phamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol, 88: 292-298, 2008.
18. Hershman D, McBride R, Jacobson JS, Lamerato L, Roberts K, GrannVR, Neugut AI: Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol, 23: 6639-6646, 2005.
19. Morrow T, Siegel M, Boone S, Lawless G, Carter W: Chemotherapy dose intensity determination as a quality of care measure for managed care organizations in the treatment of early-stage breast cancer. Am J Med Qual, 17: 218-224, 2002.
20. Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pi-lotti S, Gianni L, Valagussa P: 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ, 330: 217, 2005.
21. Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med, 304:10-15, 1981.
22. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Bram-billa C: Adjuvant cyclophosphamide, methotrexate, and fiuorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med, 332: 901-906, 1995.
23. Colleoni M, Li S, Gelber RD, Price KN, Coates AS, Cas-tiglione-Gertsch M, Goldhirsch A; International Breast Cancer Study Group: Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. Lancet, 366: 1108-1110, 2005.
24. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI: Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol, 22: 4302-4311, 2004.
25. Lyman GH, Kuderer NM: The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia. Crit Rev Oncol Hematol, 50:129-146. 2004.
26. Lyman GH, Crawford J, Dale D, Chen H, Agboola Y, Lininger L: Clinical prediction models for febrile neutropenia (FN) and relative dose intensity (RDI) in patients receiving adjuvant breast cancer chemotherapy. Proc Am Soc Clin Oncol, 20: 394A (abstract 1571), 2001.
27. Leonard RC, Miles D, Thomas R, Nussey F, UK Breast Cancer Neutropenia Audit Group: Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer, 89: 2062-2068, 2003.
28. U.S. Cancer Statistics Working Group: United States Cancer Statistics: 2004 Incidence and Mortality. US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, Atlanta, 2007.
29. ISTAT: Cause di morte: Anno 2002. ISTAT, Roma, 2005.
30. Hillner BE, Smith TJ, Desch CE: Efficacy and cost-effectiveness of autologous bone marrow transplantation in metasta-tic breast cancer. Estimates using decision analysis while awaiting clinical trial results. JAMA, 267: 2055-2061,1992.
31. Brown RE, Hutton J, Burrell A: Cost effectiveness of treatment options in advanced breast cancer in the UK. Phar-macoeconomics, 19: 1091-1102, 2001.
32. Brown RE, Hutton J: Cost-utility model comparing doc-etaxel and paclitaxel in advanced breast cancer patients. Anticancer Drugs, 9: 899-907, 1998.
33. Armstrong K, Chen TM, Albert D, Randall TC, Schwartz JS: Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk. Obstet Gynecol, 98: 996-1003, 2001.
34. Liljegren G, Karlsson G, Bergh J, Holmberg L: The cost-effectiveness of routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I. Results from a randomized trial. Ann Oncol, 8: 757-763,1997.
35. Lucioni C, Crippa L, Leoncini O: II costo di una neutropenia febbrile. Farmeconomia e Percorsi Terapeutici, 6: 21-24, 2005.
36. Rubenstein EB, Rolston K: Outpatient management of febrile episodes in neutropenic cancer patients. Support Care Cancer, 2: 369-373, 1994.
37. Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B: Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol, 23: 4198-4214, 2005.
38. García-Carbonero R, Mayordomo JI, Tomamira My López-Brea M, Rueda A, Guillem V, Arcediano A, Yubero A, Ribera F, Gómez C, Trés A, Pérez-Gracia JL, Lumbreras C, Hornedo J, Cortés-Funes H, Paz-Ares L: Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a mul-ticenter randomized trial. J Natl Cancer Inst, 93:31-38,2001.
39. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, GradisharWJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Inter-group Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol, 21: 1431-1439, 2003.
40. Marangolo M, Bengala C, Conte PF, Danova M, Pronzato P, Rosti G, Sagrada P: Dose and outcome: the hurdle of neutropenia (Review). Oncol Rep, 16: 233-248, 2006.
41. Silber JH, Fridman M, ShpilskyA, Even-Shoshan O, Smink DS, Jayaraman J, Fox KR, Pauly MV: Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. J Clin Oncol, 16:2435-2444,1998.
42. Chouaid C, Bassinet L, Fuhrman C, Monnet I, Housset B: Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model. J Clin Oncol, 16: 2700-2707, 1998.